Overactive bladder/enuresis:

Indications for VESICARE:

Overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency.


Swallow whole with water. Initially 5mg once daily; if well tolerated, may increase to 10mg once daily. Severe renal impairment (CrCl<30mL/min), moderate hepatic impairment (Child-Pugh B), or concomitant potent CYP3A4 inhibitors: max 5mg once daily.


Not established.


Gastric or urinary retention. Uncontrolled narrow-angle glaucoma.


Significant bladder outlet obstruction, decreased GI motility, high risk or history of QT prolongation, severe hepatic impairment: not recommended. Controlled narrow-angle glaucoma. Monitor for CNS effects esp. after initiation or dose increases; consider dose reduction or discontinuation if occurs. Severe renal or moderate hepatic impairment (see Adult dose). Exposure to high environmental temperature. Pregnancy. Nursing mothers.

Pharmacologic Class:

Muscarinic antagonist.


Potentiated by potent CYP3A4 inhibitors (eg, ketoconazole); see Adult dose. May be antagonized by CYP3A4 inducers. Avoid drugs known to prolong the QT interval. Additive anticholinergic effects with other anticholinergics.

Adverse Reactions:

Dry mouth, constipation, UTI, blurred vision; angioedema (discontinue if occurs), CNS effects (eg, headache, confusion, hallucination, somnolence); rare: anaphylactic reactions.

Generic Availability:


How Supplied:

Tabs—30, 90

Pricing for VESICARE

10mg tablet (Qty: 30)
Appx. price $19